Ex-Banker Walks Into a Conference, Walks Out With $480 Million
Eli Lilly & Co. agreed to buy Loxo Oncology Inc. for about $8 billion in cash in the first major deal by new CEO Dave Ricks.
Celgene Boosted the Price of Its Top Cancer Drug on the Same Day of Mega-Deal
Shareholders from Celgene and Bristol-Myers will have to approve the deal, and there are early signs they have doubts.
Celgene shareholders will get one Bristol-Myers Squibb share and $50 in cash for each Celgene share held.
Big Pharma Is Caught Between Wall Street and Trump on Drug Prices
Celgene CEO to Exit With $40 Million If He Leaves After Bristol Takeover
Acorda Rises 9.7 Percent After FDA Gives Nod for Parkinson's Therapy
Patients Fighting For Their Lives, and Helping Drug Companies While They're At It
Springer is the fourth-largest shareholder of Moderna, which hopes to make personalized cancer vaccines.
One Drug's $2.5 Billion Journey from Lab to Market
Moderna Raises $604 Million in Year's Biggest Biotech IPO
Grail had been considering raising as much as $500 million in a Hong Kong listing this year.
U.S.-China Trade Tango Threatens to Slow Biotech Money Machine
Landmark Gene-Editing Study Advances After China Crispr Clamor
Scientist Who Shocked World Drew Backing From China Biotech Push
SoftBank-Backed Biotech Roivant Climbs to $7 Billion Valuation
Moderna Therapeutics Files for IPO With $500 Million Placeholder
Alzheimer's Drug New Data Shows More Study Likely Needed
Investors Hunt for Biotech Winners as Wider Stock Market Churns
AbbVie CFO to Retire as Competition Nears for Biggest Drug